Summary

A new British startup believes that artificial intelligence is the key to speedrunning the slow and temperamental process of drug design. Potential Sciences plans to build large-scale chemical datasets by using basic principles of physics to simulate interactions between atoms, then small molecules, then complex amino acids and proteins. With that data, it’s betting it can train AI models and prediction systems capable of identifying highly targeted drugs for specific diseases, bypassing costly and time-consuming lab experimentation.

AI summaries can be wrong sometimes—always verify important details using the source article.